COLUMBIA, Md., Jun 30, 2008 (BUSINESS WIRE) -- CELSION CORPORATION (NASDAQ: CLSN) will join the Russell Microcap Index when Russell Investments reconstitutes its family of U.S. indexes on June 30, according to a list of additions posted on www.russell.com.
Membership in the Russell Microcap Index, which remains in place for one year, means auto...
COLUMBIA, Md., Jun 27, 2008 (BUSINESS WIRE) -- CELSION CORPORATION (NASDAQ: CLN) announced today that the interim results from its second Phase I liver cancer confirmation study of ThermoDox in combination with Radio Frequency Ablation (RFA) treating patients with primary and metastatic liver cancer were presented at both Oral and Poster presentati...
COLUMBIA, Md., Jun 23, 2008 (BUSINESS WIRE) -- CELSION CORPORATION (NASDAQ: CLN) announced today the change of its NASDAQ stock ticker symbol from CLN to CLSN. The new ticker symbol will go into effect at the start of trading on June 30, 2008.
"We are pleased to announce our new ticker symbol, one that we believe will improve our visibility wit...
COLUMBIA, Md., Jun 12, 2008 (BUSINESS WIRE) -- CELSION CORPORATION (NASDAQ: CLN) announced today that its docetaxel thermosensitive liposome preclinical study results will be presented at the 11th Liposome Research Days Conference. This LRD (Liposome Research Days) conference will be held from July 19 - 22, 2008 in Yokohama, Japan.
The presenta...
COLUMBIA, Md., May 15, 2008 (BUSINESS WIRE) -- Insert time of meeting in first graph so that it reads: CELSION CORPORATION (NASDAQ: CLN), will hold its Annual Meeting of Stockholders on Wednesday, May 21, 2008 at 10AM Eastern Time at the InterContinental Harbor Court Baltimore, 550 Light Street, Baltimore, MD 21202.
The corrected release reads:...
COLUMBIA, Md., May 08, 2008 (BUSINESS WIRE) -- CELSION CORPORATION (NASDAQ: CLN) today announced financial results for the first quarter ended March 31, 2008. The Company reported a net loss of $4.1 million, or $0.40 per share, compared to a net loss of $2.4 million, or $0.30 per share, for the first quarter of 2007. The results for 2007 included i...
COLUMBIA, Md., May 05, 2008 (BUSINESS WIRE) -- CELSION CORPORATION (NASDAQ: CLN), a biotechnology, drug development company that is leveraging its Heat Sensitive Liposomal Technology platform to encapsulate and deliver a high concentrations of proven chemotherapeutics, today reported that It would hold a shareholders' conference call at 11:00 a.m. ...
COLUMBIA, Md., Apr 21, 2008 (BUSINESS WIRE) -- CELSION CORPORATION (NASDAQ: CLN) announced today that the interim results from its second Phase I liver cancer confirmation study of ThermoDox in combination with Radio Frequency Ablation (RFA) treating patients with primary and metastatic liver cancer will be presented at both Oral and Poster present...
COLUMBIA, Md., Mar 19, 2008 (BUSINESS WIRE) -- CELSION CORPORATION (NASDAQ: CLN) announced today that X-ray (CT) images of liver lesions from its Phase I liver cancer study of ThermoDox in combination with RadioFrequency Ablation treating patients with primary and metastatic liver cancer were presented in an oral paper at the Society for Interventi...
COLUMBIA, Md., Mar 12, 2008 (BUSINESS WIRE) -- CELSION CORPORATION (NASDAQ: CLN) announced today that two clinical sites are currently screening patients after receiving IRB approval for the Phase III study titled "A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox®...
COLUMBIA, Md., Feb 29, 2008 (BUSINESS WIRE) -- CELSION CORPORATION (NASDAQ: CLN) announced today that the results from its Phase I liver cancer study of ThermoDox in combination with Radio Frequency Ablation treating patients with primary and metastatic liver cancer were presented during the oral paper awards session of the International Hepato-Pan...
COLUMBIA, Md., Feb 22, 2008 (BUSINESS WIRE) -- CELSION CORPORATION (NASDAQ: CLN) today announced that Dr. Ellen Jones, a Radiation Oncologist at Duke Medical Center, has been invited to present updated interim data from the current ThermoDox® study involving patients with Recurrent Chest Wall Breast Cancer (RCW...
COLUMBIA, Md., Feb 21, 2008 (BUSINESS WIRE) -- Subsequent to the end of the year, CELSION CORPORATION (NASDAQ: CLN) reported two important milestones in the development of its lead drug ThermoDox®, and in its transformation to a company totally focused on the development and commercialization of oncology drugs. On ...
Columbia, MD - February 19, 2008: CELSION CORPORATION (NASDAQ: CLN), a biotechnology, drug development company that is leveraging its Heat Sensitive Liposomal Technology platform to encapsulate and deliver a high concentrations of proven chemotherapeutics, today reported that It would hold a shareholders' conference call at 1...
Columbia, MD - February 4, 2008: CELSION CORPORATION (AMEX: CLN) announced today that Michael H. Tardugno its President and CEO is scheduled to ring the closing bell at the NASDAQ Stock Exchange at 4:00 PM on Friday, February 8, 2008, to commemorate Celsion’s listing and first day of trading on the Exchange. ...
Columbia, MD - January 28, 2008: CELSION CORPORATION (AMEX: CLN) announced today that its board of directors has approved the decision to switch the listing of its common stock from the American Stock Exchange to The NASDAQ Stock Market LLC®. Effective February 8, 2008 the company will trade under the symbol NASDAQ:CLN...
Columbia, MD - January 18, 2008: CELSION CORPORATION (AMEX: CLN) today announced that its application for a Special Protocol Assessment (SPA) for its Pivotal Phase III Primary Liver Cancer trial has been agreed to by the US Food and Drug Administration. With this agreement, Celsion will begin immediate implementation of the st...
